Clinical Trial Update: Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update examining gut microbiome changes after liraglutide treatment in obese/overweight individuals with co-morbidities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Obesity | Phase 3 | Status: UNKNOWN